These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 7679281)

  • 21. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
    Modjtahedi H; Dean C
    Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer.
    Dean CJ; Eccles SA; Valeri M; Box G; Allan S; McFarlane C; Sandle J; Styles J
    Cell Biophys; 1993; 22(1-3):111-27. PubMed ID: 7534210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice.
    Morelli D; Ménard S; Pozzi B; Balsari A; Colnaghi MI
    Cell Biophys; 1994; 24-25():119-26. PubMed ID: 7736515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epidermal growth factor receptor as a target for therapy in breast carcinoma.
    Baselga J; Mendelsohn J
    Breast Cancer Res Treat; 1994 Jan; 29(1):127-38. PubMed ID: 8018961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.
    Aboud-Pirak E; Hurwitz E; Pirak ME; Bellot F; Schlessinger J; Sela M
    J Natl Cancer Inst; 1988 Dec; 80(20):1605-11. PubMed ID: 3193478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
    Tosi E; Valota O; Negri DR; Adobati E; Mazzoni A; Meazza R; Ferrini S; Colnaghi MI; Canevari S
    Int J Cancer; 1995 Sep; 62(5):643-50. PubMed ID: 7665239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The growth-response of human tumor-cell lines expressing the EGF receptor to treatment with EGF and or mabs that block ligand-binding.
    Modjtahedi H; Styles J; Dean C
    Int J Oncol; 1993 Aug; 3(2):237-43. PubMed ID: 21573354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts.
    Stanton P; Richards S; Reeves J; Nikolic M; Edington K; Clark L; Robertson G; Souter D; Mitchell R; Hendler FJ
    Br J Cancer; 1994 Sep; 70(3):427-33. PubMed ID: 8080726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
    Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents.
    Mendelsohn J
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):889-92. PubMed ID: 2285602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.
    Panousis C; Rayzman VM; Johns TG; Renner C; Liu Z; Cartwright G; Lee FT; Wang D; Gan H; Cao D; Kypridis A; Smyth FE; Brechbiel MW; Burgess AW; Old LJ; Scott AM
    Br J Cancer; 2005 Mar; 92(6):1069-77. PubMed ID: 15770208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts.
    Kievit E; Pinedo HM; Schlüper HM; Haisma HJ; Boven E
    Br J Cancer; 1996 Feb; 73(4):457-64. PubMed ID: 8595159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
    Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
    Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.